Bone Biologics Co. (NASDAQ:BBLG) Sees Significant Decline in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) saw a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 58,200 shares, a decline of 19.3% from the October 31st total of 72,100 shares. Approximately 10.9% of the company’s shares are sold short. Based on an average daily volume of 3,010,000 shares, the days-to-cover ratio is currently 0.0 days.

Bone Biologics Stock Performance

Bone Biologics stock traded down $0.01 during midday trading on Monday, reaching $1.21. 122,571 shares of the stock traded hands, compared to its average volume of 1,465,222. Bone Biologics has a 12-month low of $0.80 and a 12-month high of $10.56. The company has a 50-day simple moving average of $1.59 and a two-hundred day simple moving average of $1.53.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.